The International AIDS Society (IAS) has announced the plenary presentations that will lead the 10th IASConference on HIV Science (IAS 2019) , which will take place in Mexico City, Mexico, on 21-24 July 2019. IAS 2019 is the largest open scientific conference on HIV and is expected to bring together more than 6,000 participants from more than 140 countries.
“These plenaries were chosen to spotlight the most urgent developments in HIV science over the past year,” IAS 2019 Co-Chair and IAS President Dr Anton Pozniak said. “They represent the very top of their field from around the world and we are honoured to have them join us for this global event.”
Among the issues under the spotlight in the IAS 2019 Plenary Programme are effective diagnosis, treatment and prevention among key populations, resource-constrained settings, implementation, co-morbidities, programme sustainability and gene- and cell-based therapies.
“This is the science that we need to step up the response to HIV, not just in Latin America, but wherever the burden of the epidemic remains high,” IAS2019 Co-Chair Dr Brenda Crabtree said. “It gets to the very heart of the most pressing issues around the epidemic right now.”
According to organizers, the IAS 2019 programme features the most critical advances in basic, clinical and operational research that moves science into policy and practice. With a diverse programme with over 90 sessions, delegates can expect to see the most breaking science of the year.
The first glimpse of the IAS 2019 programme is now available featuring the confirmed symposia and plenary sessions.
IAS 2019 plenary line-up focuses on cutting-edge issues
- New prevention products in the pipeline: A review of new prevention tools in development and data on their safety and pharmacokinetics
- Sexual and reproductive health and HIV prevention: A look at best practices in integrating HIV and sexual and reproductive health services including an examination of STI prevalence in the context of PrEP and data on interactions between PrEP and hormonal contraceptives
- HIV testing and management in the era of PrEP: A discussion of HIV testing challenges in the context of new and emerging PrEP products
- Next-generation trial design in HIV prevention: Considerations for future HIV prevention trial design as the range of prevention options
- Keep control: Elite and post-treatment controllers: Learning from the immune systems of people able to control HIV without drug
- Hide and seek: Reservoir and strategies to target them: New data on the dynamics of HIV reservoirs and the feasibility of approaches aimed at achieving a functional cure
- Kill the enemy: CTL and NK cells: Breaking insights into adaptive and innate immunity against HIV and the implications for vaccine development
- New and old players in HIV replication: New understanding of the cellular and viral factors that enhance or inhibit HIV replication and how these mechanisms can be harnessed
- Gender matters: How gender-transformative approaches are changing the HIV response: An interactive session that explores how to use data and gender analysis to improve HIV programming for women and girls in all their diversity
- PrEP, prevent, test: Increasing young key populations’ uptake of HIV prevention and testing services: Best practices in preventing HIV among young key populations including the use of social media and mobile apps to deliver tailored prevention information
- TB, opportunistic mycosis and hepatitis co-infection: A look at new data on important opportunistic infections in people living with HIV
- Political will to get to zero infections: A reflection on the importance of political will in getting to zero new infections and how to maintain high levels of political will at a global level and within countries for HIV in the face of emerging transitions and competing priorities
- Achieving HIV control: Considerations for achieving HIV epidemic control through the expansion of HIV treatment and prevention
- Ageing successfully with controlled HIV: The importance of non-communicable diseases: A look at best practices in preventing and managing co-morbidities in controlling HIV and in healthy ageing
- What is the cure, why do we need it and how do we get there?: A discussion between the community representatives, basic scientists and clinicians involved in HIV cure research on the search for a cure and how it can be achieved
Abstract-driven sessions will be announced in May, along with the launch of the full IAS 2019 online programme. More sessions and speakers will be added to the programme as they are confirmed.
More info ias2019.org